Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Work In Process: 2021-2024

  • Ascendis Pharma A's Work In Process rose 36.86% to $251.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $251.9 million, marking a year-over-year increase of 36.86%. This contributed to the annual value of $255.1 million for FY2024, which is 38.62% up from last year.
  • Per Ascendis Pharma A's latest filing, its Work In Process stood at $251.9 million for Q4 2024, which was up 36.86% from $184.0 million recorded in Q4 2023.
  • Ascendis Pharma A's Work In Process' 5-year high stood at $251.9 million during Q4 2024, with a 5-year trough of $78.8 million in Q4 2021.
  • In the last 3 years, Ascendis Pharma A's Work In Process had a median value of $184.0 million in 2023 and averaged $183.7 million.
  • Data for Ascendis Pharma A's Work In Process shows a peak YoY spiked of 59.78% (in 2023) over the last 5 years.
  • Quarterly analysis of 4 years shows Ascendis Pharma A's Work In Process stood at $78.8 million in 2021, then surged by 46.19% to $115.2 million in 2022, then skyrocketed by 59.78% to $184.0 million in 2023, then surged by 36.86% to $251.9 million in 2024.
  • Its last three reported values are $251.9 million in Q4 2024, $184.0 million for Q4 2023, and $115.2 million during Q4 2022.